drugset / Trial / NCT00016263

Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma

NCT00016263

Phase 3 Completed Genta Incorporated
RandomizedOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Oblimersen (G3139) may help dacarbazine kill more cancer cells by making tumor cells more sensitive to the drug. It is not yet known if dacarbazine is more effective with or without oblimersen (G3139). PURPOSE: Randomized phase III trial to compare the effectiveness of dacarbazine with or without oblimersen (G3139) in treating patients who have advanced malignant melanoma.

Timeline

Start
2000-07
Primary completion
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Dacarbazine Small molecule Intravenous
Subject oblimersen sodium Antisense oligonucleotide Intravenous

Indications